Arcus Biosciences - RCUS Stock Forecast, Price & News

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.

Analyst Upgrades and Downgrades

RCUS has been the topic of several recent analyst reports. SVB Leerink dropped their target price on Arcus Biosciences from $66.00 to $49.00 and set an "outperform" rating on the stock in a report on Thursday. Truist Financial lowered their target price on Arcus Biosciences from $77.00 to $50.00 and set a "buy" rating on the stock in a report on Friday, July 8th. Wedbush cut their price target on Arcus Biosciences from $42.00 to $36.00 and set an "outperform" rating for the company in a report on Thursday. Finally, Cantor Fitzgerald decreased their price objective on Arcus Biosciences from $62.00 to $48.00 in a report on Thursday. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $48.75.

Arcus Biosciences Trading Up 1.8 %

Shares of Arcus Biosciences stock opened at $27.33 on Monday. Arcus Biosciences has a twelve month low of $16.74 and a twelve month high of $49.10. The stock has a market capitalization of $1.96 billion, a P/E ratio of 38.49 and a beta of 0.71. The business's fifty day moving average price is $25.11 and its 200 day moving average price is $27.95.

Arcus Biosciences (NYSE:RCUS - Get Rating) last issued its earnings results on Wednesday, August 3rd. The company reported ($0.93) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.93). Arcus Biosciences had a return on equity of 9.12% and a net margin of 16.34%. The firm had revenue of $26.76 million for the quarter, compared to analysts' expectations of $21.00 million. During the same quarter last year, the firm earned ($1.09) earnings per share. As a group, sell-side analysts predict that Arcus Biosciences will post -4.06 EPS for the current year.

Insiders Place Their Bets

In other Arcus Biosciences news, CEO Terry J. Rosen sold 4,241 shares of the business's stock in a transaction dated Thursday, June 16th. The stock was sold at an average price of $20.72, for a total transaction of $87,873.52. Following the transaction, the chief executive officer now owns 232,329 shares in the company, valued at $4,813,856.88. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, CEO Terry J. Rosen sold 4,241 shares of Arcus Biosciences stock in a transaction dated Thursday, June 16th. The stock was sold at an average price of $20.72, for a total transaction of $87,873.52. Following the sale, the chief executive officer now directly owns 232,329 shares of the company's stock, valued at $4,813,856.88. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, President Juan C. Jaen sold 2,333 shares of Arcus Biosciences stock in a transaction dated Thursday, June 16th. The stock was sold at an average price of $20.72, for a total value of $48,339.76. Following the sale, the president now directly owns 212,574 shares in the company, valued at $4,404,533.28. The disclosure for this sale can be found here. Insiders have sold a total of 14,055 shares of company stock worth $291,220 over the last quarter. 12.70% of the stock is owned by corporate insiders.